: iStockAnalyst.com Symbols Feed

The Deep, Inner Meaning Of Bank of America's (BAC) TARP Repayment

Fri, 04 Dec 2009 14:19:07 GMT

As expected, Bank of America (BAC) will repurchase its $45 billion TARP preferreds, funded in part by an additional $18.8 billion in "common stock equivalents", $4.0 billion in asset sales, and $1.7 billion in restricted stock issued to employees in lieu of cash bonuses.[More...]

Forget Yesterday, It's All About Jobs

Fri, 04 Dec 2009 13:21:30 GMT

Good morning. Stocks tanked in the last half-hour on Thursday and while the major news outlets attributed the decline to either profit taking or some trepidation in front of this morning's big Jobs report, we'd like to offer a little more substantial reason for the 85 point dive on an otherwise subdued day of trading.[More...]

Fed Balance Sheet Declines By $15 Billion After Improbable Reduction In MBS, Excess Reserves, Monetary Base Hit Record

Fri, 04 Dec 2009 04:14:41 GMT

The Federal Reserve's balance sheet declined by $15 billion to $2,183 billion from the prior week, after the Fed presumably offloaded $2.7 billion in MBS: this is the first time since QE started that MBS holdings have declined. If anyone can tell us just who the idiots are who bought MBS from the Fed (and at what price), and who the even greater idiots are who are supposed to believe this, please send us an email.[More...]

China Will Continue To Drive The Global Economic Recovery In 2010

Thu, 03 Dec 2009 14:38:07 GMT

China isn’t just leading the global economic recovery – it’s lapping the field.[More...]

Interesting Stat: How Much Private Sector GDP Is From Construction And Real Estate?

Thu, 03 Dec 2009 13:15:56 GMT

Back in June, we discussed commercial real estate at length following attendance at a large real estate conference in NYC. Our tone was cautious and one question we wondered about was the percentage of GDP that real estate represents. We actually came across the answer back in August and meant to share then, but didn't get to it. Since the question/topic remains highly relevant to considering the potential negative economic drag from depressed real estate activity, we're sharing now -- the following table is from an 8/28/09 NYTs article, "Construction That Fueled Growth in the Sun Belt Slows":[More...]

Credit Market Overview: Dec 3, 2009

Thu, 03 Dec 2009 12:59:02 GMT

The credit crunch crisis of confidence which we appear to be crawling out of even though the debt and equity markets catapulted themselves higher earlier this year could be similarly argued to be a crisis that started in the credit markets which crunched confidence around the world as it could a collapse in confidence in the value of the securities investors held which corrupted the credit markets causing them to cease funding.[More...]

Grab Some Northern Exposure With EWC

Wed, 02 Dec 2009 21:39:42 GMT

Emerging markets are captivating investors again, but tidy profits aren’t always far away. Placing your bets on well-established global markets can also prove rewarding. That's why we're looking at Canada.[More...]

Unemployment Struggling To Turn A Corner As Job Losses Mount In November

Wed, 02 Dec 2009 21:20:20 GMT

U.S. job losses in the private sector slowed in November but still exceeded economists’ projections, a report by payroll-processing firm Automatic Data Processing (Nasdaq: ADP) indicated yesterday (Wednesday).[More...]

Why Barrick Closed Their Gold Hedge

Wed, 02 Dec 2009 19:15:14 GMT

It sure looks like gold is going to close above $1,200 an ounce today in New York. And large open market purchases from central banks in China, India and Russia are only helping the price surge more. (Just one year ago, some of these same central banks were actually selling gold in an attempt to fill an annual 10,000-ton supply gap.)[More...]

How To Profit From The 'Next' Dubai

Wed, 02 Dec 2009 13:51:42 GMT

The Dubai World default is a matter of only $60 billion – mere peanuts when compared to other elements of the global financial crisis. It’s thus of concern only to those silly enough to invest in real estate there (and the European banks foolish enough to finance it.) For the rest of us, it is a useful reminder that sudden collapses don’t really come out of nowhere – they can be foreseen, and smart investors can plan for them.[More...]

Evening Standard, London, market report column

Thu, 03 Dec 2009 18:48:00 GMT

Dec. 3--Commodity stocks should keep rising next year, but the best is behind the financials.
That's the opinion of Goldman Sachs, whose strategy suggestions for 2010 were being circulated in the City today.
Shares in London rose, with the FTSE putting on 30.71 points to 5358.10 as the banks bounced back from yesterday's losses.

[More...]

FDA OK's Agriflu seasonal flu vaccine

Mon, 30 Nov 2009 13:11:00 GMT

FDA OK's Agriflu seasonal flu vaccine[More...]

Tiffany, J. Crew, TiVo, Incyte are big movers

Wed, 25 Nov 2009 21:07:00 GMT

NEW YORK - The following stocks were among those that moved substantially or traded heavily Wednesday on the New York Stock Exchange:
Strong sales overseas and contained costs led the luxury jeweler to raise its profit outlook ahead of the holiday season.
J. Crew Group Inc., up $3.20 to $44.05

[More...]

Seasonal flu vaccine supplies spur worries

Tue, 24 Nov 2009 15:20:00 GMT

Seasonal flu vaccine supplies spur worries[More...]

New Brunswick government reimburses Lucentis(x) for residents suffering from leading cause of age-related vision loss

Mon, 16 Nov 2009 17:46:00 GMT

Wet AMD patients now have access to first medication to improve vision
DORVAL, QC, Nov. 16 /CNW Telbec/ - New Brunswickers with wet age- related macular degeneration (AMD) now have access to the new treatment Lucentis(x) (ranibizumab injection) through the New Brunswick Prescription Drug Program (NBPDP) - an important development that demonstrates the government's commitment to ensuring New Brunswick residents diagnosed with the leading cause of adult-onset vision loss receive optimal treatment.
New Brunswick now joins Newfoundland and Labrador as the only second Atlantic province to reimburse Lucentis(x), giving patients for whom the diagnosis of wet AMD could previously have meant rapidly deteriorating central vision loss and possibly even blindness , real hope to preserve and even improve vision and to maintain their independence.

[More...]

Earnings roundup: CommVault, Alcon

Wed, 28 Oct 2009 22:48:00 GMT

Among the earnings stories for Wednesday, Oct. 28, from AP Financial News:
OCEANPORT, N.J. (AP) - CommVault Systems Inc. reported a flat fiscal second-quarter profit as rising operating expenses and revenue costs overshadowed an increase in sales.
NEW YORK (AP) - Eye drug maker Alcon Inc. said its profit fell 18 percent in the third quarter compared with a year ago, when it received a large tax benefit.

[More...]

QLT Announces Third Quarter Results for 2009

Tue, 27 Oct 2009 11:48:00 GMT

QLT SEPARATELY ANNOUNCES SHARE REPURCHASE PROGRAM
VANCOUVER, Oct. 27 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today reported financial results for the third quarter ended September 30, 2009.
For the third quarter and nine months ended September 30, 2009, QLT is reporting the results of our divested QLT USA business as one line item called Income from Discontinued Operations on our statements of operations.

[More...]

UPI NewsTrack TopNews

Sat, 24 Oct 2009 17:12:00 GMT

UPI NewsTrack TopNews[More...]

UPI NewsTrack TopNews

Sat, 24 Oct 2009 12:29:00 GMT

UPI NewsTrack TopNews[More...]

CDC: 16 million flu vaccine doses shipped

Sat, 24 Oct 2009 12:07:00 GMT

CDC: 16 million flu vaccine doses shipped[More...]

AspenBio to Present at the Lazard Capital Market 6th Annual Healthcare Conference

Fri, 13 Nov 2009 15:50:00 GMT

AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-science company dedicated to the development of novel diagnostics and drugs for humans and animals, has been invited to present at the Lazard Capital Market 6th Annual Healthcare Conference to be held November 17-18, 2009 at The St. Regis Hotel New York, NY.
Company management is scheduled to present on Tuesday, November 17, 2009 at 9:25 a.m. Eastern time, with one-on-one meetings held throughout the day.
The company has a development and marketing agreement with Novartis Animal Health (NYSE: NVS) for the bovine species.

[More...]

NovaBay Pharmaceuticals Reports Third Quarter Financials and Provides Update on Pipeline of Anti-Infective Compounds

Fri, 13 Nov 2009 13:48:00 GMT

NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections, today reported financial results for the third quarter ended September 30, 2009.
For the nine months ended September 30, 2009 net cash used in operating activities was $1.5 million, due to the receipt of milestone and other cash payments from collaborative agreements, which largely offset research and development, and general and administrative expenses.
Statements regarding NovaBay's expectations that it will receive from Alcon up to $70 million in clinical milestones plus $20 million to support ongoing research and development efforts, and that it will receive from Galderma up to $50 million upon achievement of certain development and regulatory milestones, NovaBay's expectations regarding its clinical programs, including the timing of conclusions of those trials and when it will receive clinical data, as well as other statements that relate to future events or results, are forward-looking statements.

[More...]

Bernhard Hampl, Ph.D. Elected to Serve As Executive Chairman of the Board of Directors of Fresenius Kabi Pharmaceuticals Holding, Inc.

Tue, 03 Nov 2009 04:47:00 GMT

Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ), which acquired APP Pharmaceuticals, Inc., September 10, 2008, today announced the election of Bernhard Hampl, Ph.D. to its Board of Directors effective November 1, 2009.
Dr. Hampl, also named as Executive Chairman of the Board, succeeds current Chairman Dr. Ulf M. Schneider.
I am pleased to be joining the Board of Fresenius Kabi Pharmaceuticals Holding and look forward to using my experience to expand APP's pipeline, while exploring new opportunities that will position it for future growth," said Dr. Hampl.

[More...]

Alcon Posts 5.9 Percent Sales Growth for Third Quarter

Tue, 27 Oct 2009 22:50:00 GMT

Alcon, Inc. (NYSE:ACL) reported global sales rose 5.9 percent to $1,614 million for the third quarter of 2009, or a 9.0 percent increase excluding the impact of foreign exchange fluctuations.
Excluding the impact of a $240 million tax benefit related to the refractive product line in 2008 and the impact of continuing expenses related to the first quarter 2009 reduction in force, adjusted net earnings for the third quarter 2009 would have grown 33.3 percent compared to non-GAAP adjusted net earnings for the third quarter of 2008.
These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements.

[More...]

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on PCP, NVS, SPR, MUR, PG and OSK

Tue, 27 Oct 2009 11:10:00 GMT

RidgewaterEquity.com inspires to bring the best from the internet under one roof, providing you with a one click option to view what the market, researchers and financial pundits worldwide have to say about any particular large cap stocks in any given financial environment.
Once you sign up as a free member you will have free unlimited access to all our reports, research tools and more.
We have recently begun in-depth analysis of the following equities & their respective sectors:

[More...]

Synergetics USA, Inc. Announces Stay of Alcon Patent and Trademark Infringement Lawsuit

Thu, 24 Sep 2009 20:50:00 GMT

Synergetics USA, Inc. (NASDAQ: SURG), a leading medical device company that designs, manufactures, and markets innovative microsurgical instruments and other devices, today announced that the lawsuit filed by Alcon Research, Ltd. against the Company in the Northern District of Texas, Case No.
This lawsuit alleges infringement of United States Patents No.
The PTO has stated in its Ex Parte Re-examination Filing Data as of June 30, 2009, an average re-examination by the PTO takes approximately 25 months to complete.

[More...]

Novus Energy Inc. grants performance warrants and options

Fri, 04 Sep 2009 17:03:00 GMT

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./ (TSX Venture Exchange: "NVS")[More...]

NovaBay Pharmaceuticals Announces the Closing of Its $2.45 Million Registered Direct Offering of Common Stock and Warrants

Wed, 26 Aug 2009 21:49:00 GMT

Pharmaceuticals, Inc. (NYSE Amex: NBY) announced today that it has closed its previously announced registered direct offering of 1,225,000 units, with each unit consisting of (i) one share of the NovaBay common stock, par value $0.01 per share, and (ii) one warrant to purchase one share of NovaBay common stock.
The purchase price for each unit was $2.00.
Maxim Group LLC served as placement agent for the offering.

[More...]

Endo Pharmaceuticals to Partner With ProStrakan to Commercialize FORTESTA(TM) in the U.S.

Wed, 26 Aug 2009 13:46:00 GMT

CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.
Under the terms of the agreement, Endo Pharmaceuticals has agreed to make an upfront payment to ProStrakan of $10 million, with the potential for up to $40 million more in milestone payments by the end of 2010 for regulatory approval and the achievement of certain commercial milestones.
ProStrakan will exclusively supply FORTESTA to Endo Pharmaceuticals in the U.S. for an undisclosed supply price.

[More...]

Endo Pharmaceuticals Announces Cash Tender Offer for Any and All Outstanding Ledgemont PhaRMA(SM) Secured 16% Notes

Wed, 26 Aug 2009 11:50:00 GMT

CHADDS FORD, Pa., Aug. 26 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary.
The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.
The tender offer is being made pursuant to an Offer to Purchase, dated August 26, 2009, and related Letter of Transmittal, dated August 26, 2009, which set forth the terms and conditions and a more detailed description of the tender offer.

[More...]